Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer’s Disease
The present review analyzes the results of recent clinical trials of β secretase inhibition in sporadic Alzheimer’s disease (SAD), considers the striking dichotomy between successes in tests of β-site Amyloid Precursor Protein-Cleaving Enzyme (BACE) inhibitors in healthy...
Main Authors: | Vladimir Volloch, Sophia Rits |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Medical Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-3271/6/2/45 |
Similar Items
-
Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?
by: Vanessa de Jesus R. de Paula, et al. -
Icaritin, an inhibitor of beta-site amyloid cleaving enzyme-1, inhibits secretion of amyloid precursor protein in APP-PS1-HEK293 cells by impeding the amyloidogenic pathway
by: Fei Feng, et al.
Published: (2019-12-01) -
Insulin promotes amyloid precursor protein metabolism in an Alzheimer's disease cell model
by: HU Rong, et al.
Published: (2020-06-01) -
Effects of nonsteroidal anti-inflammatory drugs on amyloid-β pathology in mouse skeletal muscle
by: Tina L. Beckett, et al.
Published: (2010-09-01) -
Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimers disease
by: Xiaonan Wang, et al.
Published: (2016-03-01)